港股上市第二日，派格生物医药-B（02565）今日盘中大涨5.36%，引发市场广泛关注。这家专注于自主研发慢性病创新疗法的生物技术公司，正吸引着投资者的目光。
派格生物医药于5月27日在港交所成功上市，发行价为15.6港元/股。公司聚焦代谢紊乱相关疾病领域，重点布局包括2型糖尿病、肥胖症、非酒精性脂肪性肝炎等多个慢性代谢性疾病治疗方向。其核心产品PB-119是一款每周一次的长效GLP-1激动剂，已完成III期试验并在2023年提交国内上市申请，预计将于2025年获得NDA批准并在中国商业化推出。
分析人士指出，派格生物医药-B股价的强劲表现，主要得益于以下几个因素：首先，GLP-1赛道备受市场关注，随着肥胖症和糖尿病患者数量持续增加，该领域的市场潜力巨大；其次，公司核心产品PB-119已进入商业化冲刺阶段，有望为公司带来可观收入；最后，近期监管层对未盈利企业上市表示支持，医药IPO热潮正在回暖，这为像派格生物这样的创新生物科技企业提供了有利的融资环境。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.